-

Flatiron Health Names New Chief Business, Technology, and Product Leaders

Michael Bierl, Allison Candido, and Kate Estep assume expanded roles to drive innovation and scale.

NEW YORK--(BUSINESS WIRE)--Flatiron Health is pleased to announce three significant appointments to its Executive Team, reflecting the critical, enterprise-level responsibilities these leaders have assumed and the company’s evolving direction. Michael Bierl will serve as Chief Business Officer, Allison Candido will serve as Chief Technology Officer, and Kate Estep will serve as Chief Product Officer. With decades of combined experience, Bierl, Candido, and Estep bring the leadership and expertise needed to accelerate Flatiron’s strategy and deliver integrated data, intelligence, and point-of-care solutions that can transform cancer care globally.

Michael, Allie, and Kate’s expanded roles enable us to operate with greater clarity, coordination, and focus as we fundamentally transform how we deliver on our mission to improve and extend lives for every person with cancer.

Share

“These appointments reflect where Flatiron is headed as we build an integrated global platform that defines the future of oncology,” said Nathan Hubbard, Chief Executive Officer at Flatiron Health. “Michael, Allie, and Kate’s expanded roles enable us to operate with greater clarity, coordination, and focus as we fundamentally transform how we deliver on our mission to improve and extend lives for every person with cancer."

Michael Bierl, Chief Business Officer
Bierl joined Flatiron in 2019 and has been instrumental in shaping and scaling the company's Global Evidence business and expanding Flatiron's impact, including building and leading the company's European presence. In his role as Chief Business Officer, Bierl leads Flatiron's global commercial, scientific, clinical, operational, and customer-facing teams—reflecting how Flatiron increasingly serves customers and partners through integrated evidence solutions.

Allison Candido, Chief Technology Officer
Candido has been a foundational leader at Flatiron since 2014, bringing deep technical vision and operational excellence to all of her contributions. As Chief Technology Officer, she will continue to lead Flatiron's Engineering organization as the technology evolves its use of AI to unlock data at unprecedented scale and meet the most complex needs of customers in the oncology ecosystem.

Kate Estep, Chief Product Officer
Since joining Flatiron in 2018, Estep has earned a reputation as a deeply trusted leader, known for connecting strategy, product thinking, and customer needs across Flatiron's Point of Care and Global Evidence businesses. As Chief Product Officer, Estep will drive the evolution of Flatiron's Point of Care and Global Evidence product suites, unifying how customers across oncology providers and life sciences leverage data and AI solutions to generate intelligence that enables better decisions for life sciences partners and clinicians, accelerating progress in cancer care.

Bierl, Candido, and Estep join Cal Brouilette, Chief Financial Officer, and Julia Morton, Chief Operating Officer, on Flatiron's Executive Team, all reporting to the CEO Nathan Hubbard.

About Flatiron
Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.

Contacts

Media Contact
Nina Toor
press@flatiron.com

Flatiron Health

Details
Headquarters: New York, NY
CEO: Carolyn Starrett
Employees: 2,500
Organization: PRI

Release Versions

Contacts

Media Contact
Nina Toor
press@flatiron.com

Social Media Profiles
More News From Flatiron Health

Flatiron Health Announces 18 Research Acceptances Featuring Flatiron's Real-World Data to Be Presented at ISPOR 2026

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the ISPOR—The Professional Society for Health Economics and Outcomes Research Annual Meeting happening from May 17-20, 2026, in Philadelphia, Pennsylvania. Flatiron's high-quality real-world data and innovative research capabilities are featured across 18+ research acceptances, including seven Flatiron authored research posters as well as a panel presentation “Beyond Black Boxes: Transparent, Validated LLM Workflows for...

Flatiron Health Publishes First Peer-Reviewed Validation Framework for AI-Extracted Real-World Oncology Data in Journal of Clinical Oncology

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced the publication of the Validation of Accuracy for LLM/ML-Extracted Information and Data (VALID) Framework in the Journal of Clinical Oncology Clinical Cancer Informatics. The framework represents the first and most comprehensive, peer-reviewed approach to evaluating the quality and reliability of real-world data extracted by large language models (LLMs) and machine learning—setting a methodological benchmark for data integrity in oncolo...

Flatiron Health Attends the 2026 American Society of Genitourinary Cancers Symposium to Answer Oncology's Most Critical Questions

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the American Society of Genitourinary Cancers Symposium happening from February 26-28, 2026, in San Francisco, California. Flatiron's real-world data and research capabilities are featured across multiple presentations, including 6 research acceptances spanning genitourinary cancers. A cornerstone of Flatiron’s presence at ASCO GU 2026 is the global prostate cancer and bladder cancer Panoramic datasets, which draw from o...
Back to Newsroom